Cases & Deals

  • Home
  • Practices
  • Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeutics

Share

Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeutics

February 2021

Client(s) Nanjing Legend Biotech Co., Ltd et al

Jones Day represents Nanjing Legend Biotech Co., Ltd et al in the development and prosecution of global patent portfolios related to chimeric antigen receptor T cell (CAR-T) and other cellular therapeutics, including CARVYKTI ® and other clinical trial candidates.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.